Correlates of protection for meningococcal surface protein vaccines: lessons from the past

References

• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease [Review]. N Engl J Med. 2001 May 3;344(18):1378–1388.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1–28. .
   Google Scholar
• Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019 Sep;134:103571.
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010 Apr 22;362(16):1511–1520.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease in other countries 2017 [cited 2018 Jan 23]. Available from: https://www.cdc.gov/meningococcal/global.html
   Google Scholar
• Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):608–612.
   PubMed Web of Science ®Google Scholar
• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009 Jun 24; 27(suppl 2):B71–7.
   PubMedGoogle Scholar
• Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005 [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Vaccine. 2006 Jun 12;24(24):5093–5107.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013 Mar 7;9(6):1241–1253.
   PubMed Web of Science ®Google Scholar
• Howitz M, Krause TG, Simonsen JB, et al. Lack of association between group B meningococcal disease and autoimmune disease. Clin Infect Dis. 2007 Nov 15;45(10):1327–1334.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba [Clinical Trial, Randomized Controlled Trial]. NIPH Ann. 1991 Dec;14(2):195–210.
   Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway [clinical trial, comparative study, randomized controlled trial, research support, non-U.S. gov’t]. Lancet. 1991 Nov 2;338(8775):1093–1096.
   PubMedGoogle Scholar
• Bexsero (MenB-4C). Siena, Italy: GlaxoSmithKline Vaccines Srl; 2018.
   Google Scholar
• US Food and Drug Administration. FDA News Release. First vaccine approved by FDA to prevent serogroup B Meningococcal disease. 2014. [cited 2021 Jun 14]. Available from: https://www.fda.gov/news-events/press-announcements/first-vaccine-approved-fda-prevent-serogroup-b-meningococcal-disease
   Google Scholar
• Vaccines and Related Biologic Products Advisory Committee. Approaches to licensure of meningococcal vaccines for prevention of serogroup b invasive meningococcal disease: briefing document for the Vaccines and Related Biologic Products Advisory Committee meeting. Silver Spring, MD: U.S. Food and Drug Administration. 2011 April 7.
   Google Scholar
• Donald RG, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage [Journal Article]. Hum Vaccin Immunother. 2017;13(2):255–265.
   PubMed Web of Science ®Google Scholar
• Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012 Apr 30;30(suppl 2):B10–7.
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants [comparative study, research support, U.S. gov’t, P.H.S.]. J Clin Invest. 1975 Dec;56(6):1536–1547.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines [Research Support, Non-U.S. Gov’t]. Nat Rev Immunol. 2009 Mar;9(3):213–220.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001 Oct 15; 20(suppl 1):S58–67.
   PubMedGoogle Scholar
• Nimenrix. meningococcal group A, C, W-135 and Y conjugate vaccine. Sandwich, UK: Pfizer Ltd; 2019.
   Google Scholar
• MenQuadfi. MenACWY-TT. Swiftwater, PA: Sanofi Pasteur Inc; 2020.
   Google Scholar
• Menveo. Meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine. Sovicille (SI), Italy: GSK Vaccines, Srl; 2020.
   Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983 Aug 13;2(8346):355-3577. DOI: https://doi.org/10.1016/s0140-6736(83)90340-9.
   Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease [Review]. Hum Vaccin Immunother. 2015;11(1):5–13.
   PubMed Web of Science ®Google Scholar
• Lappann M, Otto A, Becher D, et al. Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of Neisseria meningitidis. J Bacteriol. 2013 Oct;195(19):4425–4435.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother. 2018;14(5):1058–1063.
   PubMed Web of Science ®Google Scholar
• Van De Waterbeemd B, Zomer G, Kaaijk P, et al. Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis [research support, non-U.S. gov’t]. PLoS One. 2013;8(5):e65157.
   PubMed Web of Science ®Google Scholar
• Caron F, Du Chatelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011 Jun;11(6):455–463.
   PubMed Web of Science ®Google Scholar
• De Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in sao paulo, brazil [research support, non-U.S. gov’t]. Lancet. 1992 Oct 31; 340(8827):1074–1078.
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O’Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup b disease epidemic strain [clinical trial, clinical trial, phase I, clinical trial, phase II, research support, non-U.S. gov’t]. Vaccine. 2005 Mar 18;23(17–18):2191–2196.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease [clinical trial, randomized controlled trial]. Vaccine. 2003 Jan 30;21(7–8):734–737.
   PubMed Web of Science ®Google Scholar
• Neisseria PorA typing 2019 [cited 2019 May 24]. Available from: https://pubmlst.org/neisseria/PorA/
   Google Scholar
• Neisseria porB typing 2019 [cited 2019 Nov 25]. Available from: https://pubmlst.org/neisseria/porB/
   Google Scholar
• Wang NY, Pollard AJ. The next chapter for group B meningococcal vaccines. Crit Rev Microbiol. 2018 Feb;44(1):95–111.
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R, et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents [Clinical trial, Phase II, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t]. Clin Vaccine Immunol. 2007 Jan;14(1):65–73.
   PubMed Web of Science ®Google Scholar
• De Kleijn ED, De Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age [clinical trial, randomized controlled trial Vaccine. 2000 Feb 14;18(15):1456–1466.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, Van Straaten I, Van De Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease [research support, non-U.S. gov’t]. Vaccine. 2013 Feb 4;31(7):1065–1071.
   PubMed Web of Science ®Google Scholar
• Rots NY, Kleijne DE, editors. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. 16th International Pathogenic Neisseria Conference; 2008 September 7–12; Rotterdam, Netherlands.
   Google Scholar
• Bexsero®. Summary of product characteristics. GlaxoSmithKline. 4CMenB 2019.
   Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012 Apr 30:30(suppl 2):B87–97.
   PubMedGoogle Scholar
• European Medicines Agency. Bexsero EPAR summary for the public 2012 [cited 2017 Mar 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002333/WC500137857.pdf
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004 Apr 72;(4)2088–2100.
   PubMed Web of Science ®Google Scholar
• Luo Y, Friese OV, Runnels HA, et al. The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease. AAPS J. 2016 Nov;18(6):1562–1575.
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis [research support, non-U.S. gov’t]. J Infect Dis. 2009 Aug 1;200(3):379–389.
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010 Jul 6;28(37):6086–6093.
   PubMed Web of Science ®Google Scholar
• Heist GD, Solis-Cohen S, Solis-Cohen MA. Study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. J Immunol. 1922;7(1):1–33.
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Ram S, Welsch JA, et al. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source [comparative study, evaluation studies, research support, N.I.H., extramural research support, non-U.S. gov’t]. Vaccine. 2011 Dec 9;30(1):29–34.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001 Mar;69(3):1568–1573.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO expert committee on biological standardization: twenty-seventh report Geneva, Switzerland. 1976 [cited 2018 Aug 3]. Available from: http://apps.who.int/iris/bitstream/handle/10665/37954/WHO_TRS_594.pdf?sequence=1&isAllowed=y
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines (WHO/BS/06.2041). 2006.
   Google Scholar
• Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. Methods Mol Med. 2001;66:289–304.
   Google Scholar
• Keiser PB, Gill CJ. Defining efficacy in meningococcal vaccine trials. Future Sci. 2012;2(6):589–601.
   Google Scholar
• World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines. Geneva, Switzerland: Department of Vaccines and Biologicals, World Health Organization; 1999.
   Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England [comparative study, validation studies]. Clin Diagn Lab Immunol. 2003 Sep;10(5):780–786.
   PubMedGoogle Scholar
• Borrow R, Miller E. Surrogates of protection. In: Frosch M, Maiden M, editors. Handbook of meningococcal disease. Weinheim: Wiley-VCH; 2006. p. 323–351.
   Google Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983 April 1;40(1):257–264.
   PubMed Web of Science ®Google Scholar
• Jones S. Mechanisms responsible for differential bactericidal activities of human and rabbit complement against Neisseria meningitidis [PhD thesis] Cardiff, Wales: School of Medicine, Cardiff University; 2016 [cited 2018 October 24]. Available from: https://orca.cf.ac.uk/98819/1/JonesSPhD2017.pdf
   Google Scholar
• Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera [research support, N.I.H., extramural research support, non-U.S. Gov’t]. Infect Immun. 2009 Feb;77(2):764–769.
   PubMed Web of Science ®Google Scholar
• Biagini M, Spinsanti M, De Angelis G, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2714–2719.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6(7):e1001027.
   PubMed Web of Science ®Google Scholar
• Claus H, Hubert K, Becher D, et al. A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis. Sci Rep. 2019 Feb 25;9(1):2736.
   PubMedGoogle Scholar
• Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA. 1990 May;87(10):3982–3986.
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine [comparative study, multicenter study, research support, non-U.S. gov’t]. Clin Diagn Lab Immunol. 2005 Aug;12(8):970–976.
   PubMedGoogle Scholar
• Mak PA, Santos GF, Masterman KA, et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol. 2011 Aug;18(8):1252–1260.
   PubMedGoogle Scholar
• Necchi F, Saul A, Rondini S. Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout. PLoS One. 2017;12(2):e0172163.
   PubMed Web of Science ®Google Scholar
• Nolan T, Santolaya ME, De Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37(9):1209–1218.
   PubMed Web of Science ®Google Scholar
• Findlow J, Taylor S, Aase A, et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac [clinical trial, phase II, comparative study, research support, non-U.S. gov’t]. Infect Immun. 2006 Aug;74(8):4557–4565.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Lujan E, Gibani MM, et al. Serum bactericidal antibody responses of adults immunized with the MenB-4C vaccine against genetically diverse serogroup B meningococci. Clin Vaccine Immunol. 2017 Jan 5;24(1):e00430-16. DOI:https://doi.org/10.1128/CVI.00430-16.
   Google Scholar
• Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials [in vitro validation studies]. Vaccine. 2005 Mar 18;23(17–18):2218–2221.
   PubMed Web of Science ®Google Scholar
• Iro MA, Snape MD, Voysey M, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017 Jan 5 35;(2)395–402.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013 Mar 9;381(9869):825–835.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010 Nov 15;51(10):1127–1137.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017 Dec 14;377(24):2349–2362.
   PubMed Web of Science ®Google Scholar
• Findlow J, Lowe A, Deane S, et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine. 2005 Apr 8;23(20):2623–2627.
   PubMed Web of Science ®Google Scholar
• Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B117–B125.
   PubMedGoogle Scholar
• Harris SL, Tan C, Perez J, et al. Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. Npj Vaccines. 2020; 5(8).
   PubMed Web of Science ®Google Scholar
• Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018 Jun;17(6):461–477.
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection—serum bactericidal antibody activity. Vaccine. 2005 Mar 18; 23(17–18):2222–2227.
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in iquique, chile. Chilean national committee for meningococcal disease. Vaccine. 1995;13(9):821–829.
   PubMed Web of Science ®Google Scholar
• Fischer M, Carlone GM, Holst J, et al. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine. 1999 May 14;17(19):2377–2383.
   PubMed Web of Science ®Google Scholar
• Macias Parra M, Gentile A, Vazquez Narvaez JA, et al. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: a phase 3b, randomized controlled trial. Vaccine. 2018 Nov 29;36(50):7609–7617.
   PubMed Web of Science ®Google Scholar
• Trumenba®. meningococcal group B vaccine. Philadelphia, PA: Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc); 2018.
   Google Scholar
• Bexsero®. Meningococcal Group B Vaccine. Siena, Italy: GSK Vaccines, Srl; 2018.
   Google Scholar
• Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991 Jul;4(3):359–395.
   PubMed Web of Science ®Google Scholar
• Ison CA, Anwar N, Cole MJ, et al. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb Pathog. 1999;27(4):207–214.
   PubMed Web of Science ®Google Scholar
• Morley SL, Cole MJ, Ison CA, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J. 2001 Nov;20(11):1054–1061.
   PubMed Web of Science ®Google Scholar
• Spinosa MR, Progida C, Talà A, et al. The Neisseria meningitidis capsule is important for intracellular survival in human cells. Infect Immun. 2007;75(7):3594–3603.
   PubMed Web of Science ®Google Scholar
• Longworth E, Fernsten P, Mininni TL, et al. O-Acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK. FEMS Immunol Med Microbiol. 2002 Jan 14;32(2):119–123.
   PubMedGoogle Scholar
• Beresford NJ, Martino A, Feavers IM, et al. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM(197), DT and TT glycoconjugate vaccines. Vaccine. 2017 Jun 16;35(28):3598–3606.
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Findlow J, et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun. 2001 Apr;69(4):2378–2382.
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, et al. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere 2017;2(6):e00261-17.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013 May;13(5):416–425.
   PubMed Web of Science ®Google Scholar
• Gabutti G, Stefanati A, Kuhdari P. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage [Review]. J Prev Med Hyg. 2015 Aug 31;56(3):E116–20.
   PubMedGoogle Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines [Review]. J Adolesc Health. 2016 Aug;59(suppl 2):S3–S11.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Masignani V, et al. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018 Dec;17(12):1111–1121.
   PubMed Web of Science ®Google Scholar
• Hao L, Holden MTG, Wang X, et al. Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA. Microb Genom. 2018;4(4):e000155.
   Web of Science ®Google Scholar
• NadA sequence typing 2019 [cited 2019 May 24]. Available from: https://pubmlst.org/neisseria/NadA/
   Google Scholar
• Neisseria Factor H Binding Protein Sequence Typing [cited 2018 Oct 11]. Available from: https://pubmlst.org/neisseria/fHbp/
   Google Scholar
• Neisserial heparin binding antigen (NHBA) protein sequence typing. 2019 [cited 2019 May 24]. Available from: https://pubmlst.org/neisseria/NHBA/
   Google Scholar
• Findlow J, Bayliss CD, Beernink PT, et al. Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine. 2020 Nov 17;38(49):7716–7727.
   PubMed Web of Science ®Google Scholar
• Liguori A, Dello Iacono L, Maruggi G, et al. NadA3 structures reveal undecad coiled coils and LOX1 binding regions competed by meningococcus B vaccine-elicited human antibodies. mBio. 2018 Oct 16;9(5). https://doi.org/10.1128/mBio.01914-18.
   Google Scholar
• Partridge E, Lujan E, Giuntini S, et al. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine. 2017 Jul 24;35(33):4236–4244.
   PubMed Web of Science ®Google Scholar
• Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol. 1991 Jan;21(1):11–16.
   PubMed Web of Science ®Google Scholar
• Boan P, Metasan N, Tempone S, et al. Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011. BMC Infect Dis. 2014 Dec 12;14:686.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein [research support, non-U.S. gov’t]. Clin Vaccine Immunol. 2011 Jun;18(6):1002–1014.
   PubMedGoogle Scholar
• Green LR, Lucidarme J, Dave N, et al. Phase variation of NadA in invasive Neisseria meningitidis isolates impacts on coverage estimates for 4C-MenB, a MenB vaccine. J Clin Microbiol. 2018;56(9):e00204–18.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834–10839.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Bartolini E, Galli B, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018 Feb 27;8(1):3700.
   PubMedGoogle Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial [clinical trial, phase II, comparative study, randomized controlled trial, research support, non-U.S. gov’t]. Pediatr Infect Dis J. 2010 Nov;29(11):e71–9.
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Santini L, et al. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Hum Vaccin Immunother. 2019;15(3):725–731.
   PubMed Web of Science ®Google Scholar
• Brunelli B, Del Tordello E, Palumbo E, et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine. 2011 Jan 29;29(5):1072–1081.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490–19495.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study [Observational Study]. Lancet. 2016 Dec 03;388(10061):2775–2782.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease-United States, 1996-2015. Clin Infect Dis. 2018;66(8):1276–1281.
   PubMed Web of Science ®Google Scholar
• Isitt C, Cosgrove CA, Ramsay ME, et al. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020 Aug;105(8):784–790.
   PubMed Web of Science ®Google Scholar
• Wedege E, Bolstad K, Aase A, et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines [clinical trial, phase I, clinical trial, phase II, comparative study, research support, non-U.S. gov’t]. Clin Vaccine Immunol. 2007 Jul;14(7):830–838.
   PubMedGoogle Scholar
• Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB [comparative study, research support, non-U.S. gov’t]. Clin Vaccine Immunol. 2006 Apr;13(4):486–491.
   PubMedGoogle Scholar
• Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–3330.
   PubMed Web of Science ®Google Scholar
• Vermont CL, Van Dijken HH, Kuipers AJ, et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun. 2003 Apr;71(4):1650–1655.
   PubMed Web of Science ®Google Scholar
• Findlow J, Holland A, Andrews N, et al. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay. Clin Vaccine Immunol. 2007 Nov;14(11):1451–1457.
   PubMedGoogle Scholar
• Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact [research support, non-U.S. gov’t]. Vaccine. 2013 May 28 31;(23)2638–2646.
   PubMed Web of Science ®Google Scholar
• Christensen H, Irving T, Koch J, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germany. Vaccine. 2016 Jun 17;34(29)3412–3419.
   PubMed Web of Science ®Google Scholar
• Lecocq H, Parent Du Chatelet I, Taha MK, et al. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240–2250.
   PubMed Web of Science ®Google Scholar